Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis: Figure 1

Tabassi, N. Charni-Ben; Richardot, P.; Toh, Ling; Marotte, Hubert; Bay‐Jensen, Anne‐Christine; Miossec, Pierre; Garnero, Patrick

doi:10.1136/ard.2008.097915

Cited by 7 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…Several years later, it was demonstrated-by direct sequencing of human cartilage type II collagenthat the previously published sequence was incorrect, 31 therefore making the specificity of Helix-II for type II collagen questionable. The presence of 4-hydroxyproline is a key point for antibody recognition as demonstrated by Charni-Ben Tabassi et al 29 in 2005. Thus, a potential target for the Helix-II antibody is type III collagen because the GTS sequence and the 4-hydroxyproline at the P * site of 183-GPP * GTS-188 are both present in the sequence of human type III collagen.…”

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 96%

“…Interestingly the levels of serum IIINys were also markedly elevated (+207%) in patients with RA and the IIINys epitope detected by immunohistochemistry was highly expressed by the inflammed synovial tissue. 29,30 Helix-II marker. The Helix-II is a biological marker that was initially developed to measure the degradation of the helical portion of human type II collagen.…”

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 99%

See 2 more Smart Citations

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 96%

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 99%

See 1 more Smart Citation

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…In patients with joint disorder, the synovial membrane contains nitrated proteins [42]. IIINys was increased in serum from OA patients [43] and RA patients [44]. Its level was the highest in RA patients which suggests that it is related to synovial tissue inflammation [44].…”

Section: Synovial Biomarkersmentioning

confidence: 99%

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Denarié

Constant

Thomas

et al. 2014

Mediators of Inflammation

View full text Add to dashboard Cite

Objective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission. Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission. IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required. Cartilage Biomarkers. Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described. This unbalance is also associated with joint destruction and prognosis of destruction. No data are available on patients in remission. Bone Biomarkers. RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP. RA therapies seem to improve bone turnover in limiting bone resorption. There is no study about bone marker utility in remission. Conclusion. Biomarkers seem to correlate with RA activity and progression. They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.

show abstract

“…Due to various reasons, the production of ROS increases, or the body's ability to clear ROS decreases, and the body will experience oxidative stress. When the body is in a state of oxidative stress, the amount of ROS in tissue cells in the body is relatively increased, which exceeds the body's ability to clear, leading to an increase in the level of lipid peroxidation in the body tissues, causing DNA oxidative damage and abnormal protein expression, causing damage to the body [7]. Nitrated proteins (ROS oxidized proteins) in OA cartilage tend to be distributed on the surface of cartilage tissue, which indicates that there are more toxic ROS aggregates in the surface cells of OA cartilage tissue [8].…”

Section: Introductionmentioning

confidence: 99%

piRNA hsa_piR_019914 promoted chondrocyte anabolic metabolism by inhibiting LDHA-dependent ROS production

Gao

Yan

Sun

2023

Preprint

View full text Add to dashboard Cite

Objectives As a new molecular marker and therapeutic target, Piwi-interacting RNA(piRNA) has been widely studied in the field of oncology, but few people have studied the role of piRNA in osteoarthritis. Here, we found that the expression of hsa_piR_019914 in human osteoarthritis cartilage decreased significantly. We studied the relationship between hsa_piR_019914 and gene expression in osteoarthritis cartilage and the role of hsa_piR_019914 in chondrocyte biology. It is suggested that hsa_piR_019914 may be a new target for the treatment of osteoarthritis. Design Using the GEO database to analyze the expression of piRNA in the cartilage of osteoarthritis, using qPCR to detect the effect of inflammatory factors on the expression of piRNA in chondrocytes, using CCK-8 and clone formation to detect the effect of hsa_piR_019914 on chondrocyte proliferation, and using flow cytometry to detect the effect of hsa_piR_019914 on chondrocyte apoptosis and ROS production. The target gene of hsa_piR_019914 regulation was detected by mRNA sequencing. Results GEO data analysis found that 11 piRNAs were downregulated in cartilage tissue of osteoarthritis, and inflammatory factors inhibited the expression of hsa_piR_019914 in chondrocytes. Hsa_piR_019914 promoted the proliferation of chondrocytes and the synthesis of extracellular matrix. Hsa_piR_019914 inhibited the apoptosis of chondrocytes and the expression of cell-matrix protease. Hsa_piR_019914 targets regulating the expression of LDHA and inhibiting the production of ROS. Conclusions This work highlights the role of hsa_piR_019914 in chondrocyte metabolism, the inhibition of LDHA, and the reduction of ROS production, which may be used as a potential treatment for osteoarthritis.

show abstract

Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis: Figure 1

Cited by 7 publications

References 8 publications

Soluble biological markers in osteoarthritis

Soluble biological markers in osteoarthritis

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

piRNA hsa_piR_019914 promoted chondrocyte anabolic metabolism by inhibiting LDHA-dependent ROS production

Contact Info

Product

Resources

About